Aclaris Therapeutics ACRS Drug Discovery Platform — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's drug discovery platform — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's drug discovery platform — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug discovery platform — research and development project spend of $1.44M in Q1 2026.
- How has Aclaris Therapeutics's drug discovery platform — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug discovery platform — research and development project spend increased by 115.4% year-over-year, from $668K to $1.44M.
- What does drug discovery platform — research and development project spend mean?
- This metric represents the total capital and operational expenditure allocated specifically to research and development activities within the drug discovery platform segment. It reflects the company's investment intensity in advancing its pipeline of novel therapeutic candidates and early-stage scientific innovation. Monitoring this spend helps investors assess the company's commitment to long-term growth and the pace of its internal drug development efforts.